Bone

EQS-News: How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication

Retrieved on: 
Friday, September 23, 2022

Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States.

Key Points: 
  • Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States.
  • In fact, each year, more people die from this silent killer than from breast or prostate cancer.
  • Hyperphosphatemia (elevated phosphorus levels in the blood) is a common complication of CKD affecting over 80% of dialysis patients.
  • UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury.

Signify Health Receives NCQA’s HEDIS Allowable Adjustments Certification

Retrieved on: 
Wednesday, September 21, 2022

More than 90 percent of health plans in the United States, covering 190 million people, rely on NCQAs HEDIS measurement tool.

Key Points: 
  • More than 90 percent of health plans in the United States, covering 190 million people, rely on NCQAs HEDIS measurement tool.
  • Through our comprehensive data set and analytics, Signify Health is able to effectively identify at-risk patients and connect them with the appropriate diagnostic and preventive services, said Marc Rothman, MD, Chief Medical Officer, Signify Health.
  • In 2021, Signify Health announced the certifications for diabetes care, kidney health evaluation in patients with diabetes, colorectal cancer screening, and osteoporosis management in women.
  • NCQAs Healthcare Effectiveness Data and Information Set (HEDIS) is the most widely used performance measurement tool in health care.

Quince Therapeutics Presents Preclinical Data at MHSRS 2022 Demonstrating Preclinical Efficacy of Bone-targeting Platform for Traumatic Bone Injury

Retrieved on: 
Friday, September 16, 2022

At MHSRS 2022, Quince presented a poster showcasing the broad applicability of the companys highly differentiated bone-targeting platform and potential to accelerate healing directly at the site of bone injury in traumatic indications.

Key Points: 
  • At MHSRS 2022, Quince presented a poster showcasing the broad applicability of the companys highly differentiated bone-targeting platform and potential to accelerate healing directly at the site of bone injury in traumatic indications.
  • NOV004 is a fracture-targeted bone anabolic agent that concentrates selectively on the bone fracture surface and induces accelerated bone formation only at the damaged site.
  • In preclinical studies, Quince observed a decrease in fracture healing time by 50% in NOV004 treated groups.
  • To view the poster presented at MHSRS 2022, please visit the Science section of Quinces corporate website .

New Leaf Paper achieves Benefit Corporation status

Retrieved on: 
Friday, September 16, 2022

APPLETON, Wis., Sept. 16, 2022 /PRNewswire/ -- New Leaf Paper (NLP) is now listed on the Benefit Corporation register, which allows the company to meet the legal requirement for B Corp certification.

Key Points: 
  • APPLETON, Wis., Sept. 16, 2022 /PRNewswire/ -- New Leaf Paper (NLP) is now listed on the Benefit Corporation register, which allows the company to meet the legal requirement for B Corp certification.
  • As a Benefit Corporation, we are required to regularly report publicly on how the company is achieving these goals.
  • "New Leaf Paper is committed to being a leader in sustainability in the paper industry and to providing our customers with sustainable solutions that reach beyond their paper products.
  • New Leaf Paper is the leading national supplier of environmentally responsible paper solutions, focusing on developing and supplying sustainable, superior papers with 100% post-consumer recycled fiber (PCRF).

Wellness Pioneer Russell Jaffe, MD, PhD, CCN and Bone Health Expert Susan Brown, PhD, CNS, Launch Book, "Natural Bone Health: A Practitioner's Guide to Healthy Bone, Joints and Muscles."

Retrieved on: 
Friday, September 16, 2022

ASHBURN, Va., Sept. 16, 2022 /PRNewswire/ -- Osteoporosis is a complex and multifactorial disorder that is growing in prevalence. More than half of Medicare-aged women and more than a fifth of comparable age men have one or more osteoporotic fractures confirmed during their lifetime. Recovery from large bone fractures is slow and leads to a more sedentary and less engaged life with greater morbidity and accelerated mortality.

Key Points: 
  • "Natural Bone Health: A Practitioner's Guide to Healthy Bone, Joints and Muscles" is now available for purchase.
  • Those who diligently work through the steps of our program put control back into their control systems, gain bone strength, and reduce fracture risk."
  • Natural Bone Health: A Practitioner's Guide to Healthy Bone, Joints and Muscles is now available for purchase on Amazon.com and at https://www.perqueintegrativehealth.com/natural-bone-health-a-practition...
    Russell Jaffe, MD, Ph.D., CCN, is an internist and immunologist.
  • Dr. Jaffe helped advance several adjunctive healthcare approaches including medical acupuncture (TCM), certified clinical nutrition (CCN), health coaching, and predictive biomarkers.

Profound Medical Announces Changes to its Commercial Organization to Support Continued Growth

Retrieved on: 
Thursday, September 15, 2022

At the same time, we are excited that he is leaving our commercial organization in such good hands.

Key Points: 
  • At the same time, we are excited that he is leaving our commercial organization in such good hands.
  • Ms. Goodman brings over 17 years of medical device sales experience, most recently serving as Profounds VP, U.S.
  • Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
  • Profound is commercializing TULSA-PRO, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control.

Quince Therapeutics Presents Preclinical Data at ASBMR 2022 Demonstrating Application of Bone-targeting Platform for Spinal Fusion and Bone Cancer Indications

Retrieved on: 
Monday, September 12, 2022

At ASBMR 2022, Quince presented two posters showcasing the broad applicability of the companys highly differentiated bone-targeting platform and potential to accelerate healing directly at the site of bone injury and disease in spinal fusion and bone cancer indications.

Key Points: 
  • At ASBMR 2022, Quince presented two posters showcasing the broad applicability of the companys highly differentiated bone-targeting platform and potential to accelerate healing directly at the site of bone injury and disease in spinal fusion and bone cancer indications.
  • We are excited to continue to bring our preclinical research forward to demonstrate the potential of our proprietary targeting platform with additional indications in spinal fusion and bone cancer as we seek to improve outcomes in underserved patient populations.
  • The following are highlights from the companys poster presentations of preclinical data exploring spinal fusion and bone cancer indications at ASBMR 2022:
    With more than 400,000 spinal fusions performed in the U.S. every year, Quince believes there is an opportunity to utilize its bone-targeting platform to improve patient outcomes in spinal fusion with its NOV004 targeted therapeutic.
  • Quince developed a bone-targeting compound based on acidic oligopeptides which is designed to stimulate bone growth at spinal fusion sites.

CORRECTION: Bioretec's hybrid composite patent has been approved in Europe

Retrieved on: 
Friday, September 9, 2022

TAMPERE, Finland, Sept. 9, 2022 /PRNewswire/ -- The European Patent Office has announced to approve Bioretec Oy's hybrid composite material patent application EP3782657A1 and will grant and publish the patent after the Company's confirmation.

Key Points: 
  • TAMPERE, Finland, Sept. 9, 2022 /PRNewswire/ --The European Patent Office has announced to approve Bioretec Oy's hybrid composite material patent application EP3782657A1 and will grant and publish the patent after the Company's confirmation.
  • Approved patent concerns magnesium-based reinforced composite material, i.e., hybrid composite.
  • The patent also includes the usage of the hybrid composite material in the manufacturing of a medical device or a part of such a device.
  • The patent application process for the hybrid composite material in regions outside of Europe continues based on the international PCT patent application WO2021032882A1, and the Company will inform about patent approvals in other regions as the application process progress.

CORRECTION: Bioretec's hybrid composite patent has been approved in Europe

Retrieved on: 
Friday, September 9, 2022

TAMPERE, Finland, Sept. 9, 2022 /PRNewswire/ -- The European Patent Office has announced to approve Bioretec Oy's hybrid composite material patent application EP3782657A1 and will grant and publish the patent after the Company's confirmation.

Key Points: 
  • TAMPERE, Finland, Sept. 9, 2022 /PRNewswire/ --The European Patent Office has announced to approve Bioretec Oy's hybrid composite material patent application EP3782657A1 and will grant and publish the patent after the Company's confirmation.
  • Approved patent concerns magnesium-based reinforced composite material, i.e., hybrid composite.
  • The patent also includes the usage of the hybrid composite material in the manufacturing of a medical device or a part of such a device.
  • The patent application process for the hybrid composite material in regions outside of Europe continues based on the international PCT patent application WO2021032882A1, and the Company will inform about patent approvals in other regions as the application process progress.

Bioretec's hybrid composite patent has been approved in Europe

Retrieved on: 
Thursday, September 8, 2022

TAMPERE, Finland, Sept. 8, 2022 /PRNewswire/ -- The European Patent Office has announced to approve Bioretec Oy's hybrid composite material patent application EP3782657A1 and will grant and publish the patent after the Company's confirmation.

Key Points: 
  • Approved patent concerns magnesium-based reinforced composite material, i.e., hybrid composite.
  • The patent also includes the usage of the hybrid composite material in the manufacturing of a medical device or a part of such a device.
  • The patented hybrid composite material will be used in those products of Bioretec's RemeOs product family that require very high load-bearing capacity.
  • The patent application process for the hybrid composite material in regions outside of Europe continues based on the international PCT patent application WO2021032882A1 and the Company will inform about patent approvals in other regions as the application process progress.